According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
Other research analysts also recently issued research reports about the stock. Piper Jaffray Cos. began coverage on shares of Audentes Therapeutics in a research report on Monday, August 15th. They issued an overweight rating and a $24.00 price objective on the stock. Cowen and Company began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an outperform rating for the company. Finally, Wedbush began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an outperform rating and a $20.00 target price for the company.
Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at 19.01 on Wednesday. Audentes Therapeutics has a 52 week low of $13.06 and a 52 week high of $20.74. The stock’s market capitalization is $412.99 million. The stock has a 50 day moving average of $16.39 and a 200-day moving average of $15.74.
In related news, major shareholder Versant Ventures Iv, Llc bought 35,000 shares of the stock in a transaction that occurred on Monday, July 25th. The stock was bought at an average cost of $15.00 per share, for a total transaction of $525,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider James E. Flynn bought 400,000 shares of the stock in a transaction that occurred on Monday, July 25th. The stock was bought at an average price of $15.00 per share, with a total value of $6,000,000.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.